Study | Year | Country | Design | Assay Type | Reference Standard | Control Group†|
---|---|---|---|---|---|---|
Tomcsanyi et al[16] | 2004 | Hungary | PC | ECLIA(1)‡ | Clinical Criteria* a, b, c, e | 57% M; 14% I; 29% O |
Porcel et al[17] | 2004 | Spain | PC | ECLIA(1) | Clinical Criteria* a, b, c, d, e, f | NR |
Kolditz et al[18] | 2006 | Germany | PC | ECLIA(1) | Clinical Criteria* a, b, c, e, f | 59% M; 21% I; 30% O |
Porcel et al[19] | 2007 | Spain | PC | ECLIA(1) | Clinical Criteria* a, b, c, d, e, f | 48% M; 20% I; 32% O |
Liao et al[20] | 2008 | USA | PC | ELISA | Clinical Criteria* a, c, e | 25% M; 0% I; 75% O |
Han et al[21] | 2008 | Korea | PC | ECLIA(1) | Clinical Criteria* a, b, e, f | 24% M; 66% I; 10% O |
Seyhan et al[22] | 2009 | Turkey | PC | ECLIA | Clinical Criteria* N/A | N/A |
Porcel et al[23] | 2009 | Spain | RC | ECLIA(2) | Clinical Criteria* a, b, c, e, f | 44% M; 29% I; 27% O |
Bayram et al[24] | 2009 | Turkey | PC | ECLIA(1) | Clinical Criteria* a, b, c, e, f | 23% M; 31% I; 46% O |
Long et al[25] | 2010 | USA | RC | ELISA | Clinical Criteria* a, b, c, e | 25% M; 25% I; 25% O |